Dabur: In the reckoning - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dabur: In the reckoning

Aug 31, 2000

Dabur India, the 115 year old FMCG ‘ayurvedic’ company operates in the niche natural/ayurvedic products segment with a product folio of over 500 products. Its core competence lies in its ability to conceive, develop and market products based on herbs and natural resources. Its product portfolio includes major brands like Dabur Chyawanprash, Hajmola, Pudin Hara, Lal Dant Manjan, Amla, Vatika hair oils, Real fruit juice, Dabur Honey, all of which are market leaders in their respective segments. It is also a leading player in the anti-cancer segment and was the first company in India to have developed the anti-cancer intermediary DAB-10 and its associated drug paclitaxel (Taxol). But despite its range, investors have been wary of investing in this company simply because of its unrelated diversifications and a family run business. To counter this, Dabur undertook a restructuring exercise about a couple of years ago, based on McKinsey recommendations. As a result, it decided to spin off non-core businesses and inducted an all-new professional management team.

The markets took notice of these initiatives and stock price climbed. But lately, Dabur has been facing the music on the bourses. The company’s stock is quoting at Rs 690 levels, which is 25.7 times its FY2000 earnings. At its 52 week peak, the company quoted at a P/e multiple of over 60 times.

This is despite a 53% growth in net profit for the year ended March 2000 over the previous year. The growth in sales amounted to 13.4%. This is by any yardstick a creditable performance when most FMCG companies (including HLL) are clocking single digit turnover growth. Its margins also showed a marked improvement over the previous year. However, in its first quarter the company has shown signs of slowing down. Turnover growth slowed to 7%, compared to a 19% growth in 1QFY99. But its profits logged in a 33% growth, showing signs of improving margins. So it’s showing has been decent.

But there are some concerns. Lately, the company has again been dabbling in diversifications, like its proposed foray into life insurance (in partnership with US insurance company Allstate). Dabur is entering processed milk segment via its joint venture company Dabon. The company has also downgraded its earnings estimates and has stated that it will be unable to achieve the sales target of Rs 20 bn by FY2003 ( FY2000 turnover = Rs 10.8 bn).

However, such issues notwithstanding, the company’s presence in a niche industry of ayurveda products, strong brands, and diverse product portfolio, backed by strong research, serves as an entry barrier for new entrants and is difficult to replicate. One should take into account Dabur’s extensive distribution reach (over 600,000 retailers) in India. Moreover, the company’s management looks committed to improving the company’s core operations by getting out of low margin businesses and pruning the debt burden.

Bottomline, it is time for a relook.


Equitymaster requests your view! Post a comment on "Dabur: In the reckoning". Click here!

  

More Views on News

DABUR Announces Quarterly Results (1QFY21); Net Profit Down 6.1% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, DABUR has posted a net profit of Rs 3 bn (down 6.1% YoY). Sales on the other hand came in at Rs 20 bn (down 12.9% YoY). Read on for a complete analysis of DABUR's quarterly results.

DABUR Announces Quarterly Results (4QFY20); Net Profit Down 24.1% (Quarterly Result Update)

May 29, 2020 | Updated on May 29, 2020

For the quarter ended March 2020, DABUR has posted a net profit of Rs 3 bn (down 24.1% YoY). Sales on the other hand came in at Rs 19 bn (down 12.3% YoY). Read on for a complete analysis of DABUR's quarterly results.

DABUR 2018-19 Annual Report Analysis (Annual Result Update)

Sep 30, 2019 | Updated on Sep 30, 2019

Here's an analysis of the annual report of DABUR for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DABUR. Also includes updates on the valuation of DABUR.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DABUR SHARE PRICE


Sep 25, 2020 (Close)

TRACK DABUR

DABUR - TIGER BRANDS COMPARISON

COMPARE DABUR WITH

MARKET STATS